Columbia University Division of Cardiology, Mount Sinai Medical Center, Miami Beach, FL, USA.
Miller School of Medicine, The University of Miami, Miami, FL, USA.
J Interv Cardiol. 2020 Jul 21;2020:1789516. doi: 10.1155/2020/1789516. eCollection 2020.
Transcatheter aortic valve replacement (TAVR) is now the treatment of choice for patients with severe aortic stenosis regardless of their surgical risk. Right bundle branch block (RBBB) can be a predictor for development of significant atrioventricular (AV) block after TAVR, requiring permanent pacemaker implantation (PPI). However, data related to the risk of PPI requirement with preexisting RBBB is scarce. Hence, this systematic review and meta-analysis aims to assess clinical outcomes of patients undergoing TAVR with RBBB on preexisting electrocardiogram.
We performed a systematic literature review to identify randomized and nonrandomized clinical studies that reported any clinical impact of patients undergoing TAVR with preexisting RBBB. A total of eight databases including PubMed (Medline), Embase, Cochrane Library, ACP Journal Club, Scopus, DARE, and Ovid containing articles from January 2000 to May 2020 were analyzed.
We identified and screened 224 potential eligible publications through the databases and found 14 relevant clinical trials for a total of 15,319 participants. There was an increased 30-day pacemaker implantation rate of 38.1% in the RBBB group compared to 11.4% in the no RBBB group with a risk ratio of 3.56 (RR 3.56 (95% CI 3.21-3.93, < 0.01)). There was an increased 30-day all-cause mortality in the RBBB group of 9.5% compared with 6.3% in the no RBBB group with an odds ratio of 1.60 (OR 1.60 (95% CI 1.14-2.25, < 0.01)).
This study indicates that patients with preexisting RBBB have higher incidence of PPI and all-cause mortality after TAVR compared with patients without RBBB. Further trials are needed to compare the clinical outcomes based on TAVR valve types and assess the benefit of PPI in patients with new-onset RBBB after TAVR.
经导管主动脉瓣置换术(TAVR)现已成为严重主动脉瓣狭窄患者的首选治疗方法,无论其手术风险如何。右束支传导阻滞(RBBB)可预测 TAVR 后发生显著房室(AV)传导阻滞,需要植入永久性起搏器(PPI)。然而,关于 TAVR 前存在 RBBB 患者植入 PPI 的风险数据很少。因此,本系统回顾和荟萃分析旨在评估 TAVR 前存在 RBBB 的患者的临床结局。
我们进行了系统的文献综述,以确定报告 TAVR 前存在 RBBB 的患者任何临床影响的随机和非随机临床研究。总共分析了包括 PubMed(Medline)、Embase、Cochrane 图书馆、ACP 期刊俱乐部、Scopus、DARE 和 Ovid 在内的 8 个数据库,这些数据库包含了 2000 年 1 月至 2020 年 5 月的文章。
我们通过数据库筛选了 224 篇潜在的合格文献,并发现了 14 项相关临床试验,共涉及 15319 名参与者。RBBB 组的 30 天起搏器植入率为 38.1%,而无 RBBB 组为 11.4%,风险比为 3.56(RR 3.56(95% CI 3.21-3.93,<0.01))。RBBB 组 30 天全因死亡率为 9.5%,而无 RBBB 组为 6.3%,优势比为 1.60(OR 1.60(95% CI 1.14-2.25,<0.01))。
这项研究表明,与无 RBBB 的患者相比,TAVR 前存在 RBBB 的患者植入 PPI 和全因死亡率更高。需要进一步的试验来比较基于 TAVR 瓣膜类型的临床结局,并评估 TAVR 后新发 RBBB 患者植入 PPI 的获益。